CSF2 and cancer: Preferential lysis of cancer cells leads to the release of danger signals and tumor‐associated antigens, which trigger potent adaptive anti‐tumor responses.[213] T‐VEC is an oncolytic herpes simplex virus type 1 (HSV‐1) that attenuates selective cancer cell replication and encodes GM‐CSF to promote local accumulation of DCs and facilitate antitumor immune responses.